FIELD: pharmaceutics.
SUBSTANCE: present invention refers to biotechnology, specifically engineered polypeptides with serum albumin binding affinity, and can be used in medicine. Produced is a polypeptide binding serum albumin, containing a sequence of: LA[E,S,Q,C]AK[E,S,C][A,S]AN[A,S,R]ELD[A,S,C,K]YGVSDFYKRLI[D,E]KAKTVEGVEALK[D,E][A,E]IL[A,K][A,S,E]LP, wherein L45 and P46 are present or absent, a fusion protein and polypeptide conjugate with the desired biological activity to prolong a blood half-life and/or reduce immunogenicity of a second polypeptide, as well as polynucleotides coding the produced polypeptide and fusion protein, and a composition for increasing water solubility of the compound.
EFFECT: invention allows to produce the stable polypeptide binding serum albumin, with the improved affinity to human serum albumin and reduced immunogenicity, able to increase the blood half-life and/or reduce immunogenicity of the polypeptide with the desired biological activity.
20 cl, 13 dwg, 5 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF ALBUMIN | 2010 |
|
RU2607374C2 |
| ALBUMIN VARIANTS | 2013 |
|
RU2670063C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5 | 2013 |
|
RU2654668C2 |
| NOVEL POLYPEPTIDES | 2014 |
|
RU2681428C2 |
| VERSIONS OF ALBUMIN | 2012 |
|
RU2650784C2 |
| ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | 2015 |
|
RU2710787C2 |
| NUCLEIC ACIDS ENCODING ANTIBODIES AGAINST SIALYLATED HUMAN LEWIS ANTIGEN | 2014 |
|
RU2791967C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY TO CERTAIN TARGET | 2010 |
|
RU2564125C2 |
| NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS | 2014 |
|
RU2699289C2 |
